Articles from argenx SE

$737 million in fourth quarter and $2.2 billion in full year global product net sales

February 25, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025 at 11:50 a.m. ET.

February 20, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 27, 2025 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2024 financial results and provide a fourth quarter business update.

November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December.

        

VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe

Regulated information – Inside information

Regulated information — Inside information

Regulated information — Inside information

Regulated information — Inside information

January 27, 2023

January 16, 2023

Reported $402 million in preliminary* full-year 2022 global net VYVGART sales